Müller P, Dammann H G, Marinis E, Weise D, Simon B
Fortschr Med. 1989 Oct 30;107(31):667-70.
339 patients with rheumatic diseases suffering from dyspepsia and endoscopically proven gastroduodenal lesion entered an open multicenter study with ranitidine 150 mg bid or ranitidine 300 mg administered at night in a single dose over 4 weeks. For entry the patients had to have been treated for at least 3 months with the non-steroidal anti-inflammatory drugs diclofenac, indomethacin and piroxicam. During the trial all patients were continued on NSAID. The data of 248 patients were evaluable. At entry, patients in both treatment groups had a total gastric damage score of 2.0. The duodenal lesion score was on average 1.43 in the ranitidine 150 mg bid group, and 1.8 in the 300 mg single dose ranitidine at night group. After 4 weeks of treatment the mean lesion score was significantly reduced in the stomach as well as in the duodenum with both ranitidine regimens, no differences being seen between the groups. In addition, rapid symptomatic relief was observed in both groups. After 4 weeks of treatment more than 80% of the patients were symptom-free or markedly improved.
339例患有消化不良且经内镜证实有胃十二指肠病变的风湿性疾病患者进入一项开放的多中心研究，接受雷尼替丁治疗，其中150毫克，每日两次，或雷尼替丁300毫克，每晚单剂量给药，为期4周。入选患者必须已使用双氯芬酸、吲哚美辛和吡罗昔康等非甾体抗炎药治疗至少3个月。在试验期间，所有患者继续使用非甾体抗炎药。248例患者的数据可评估。入选时，两个治疗组患者的胃损伤总评分均为2.0。在雷尼替丁150毫克每日两次组中，十二指肠病变评分平均为1.43，在每晚300毫克单剂量雷尼替丁组中为1.8。两种雷尼替丁治疗方案治疗4周后，胃和十二指肠的平均病变评分均显著降低，两组之间未见差异。此外，两组均观察到症状迅速缓解。治疗4周后，超过80%的患者无症状或明显改善。
